Investors

Press Releases

 
Press Releases
  Date Title View
Sep 16, 2010
Watertown, MA – September 16, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative p...
Sep 15, 2010
Watertown, MA – September 15, 2010 – Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens. The data supported the utility ...
Sep 15, 2010
Watertown, MA –  September 15, 2010 – Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative ...
Sep 13, 2010
Watertown, MA – September 13, 2010 –Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once-daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant Gram-negative pathogens while als...
Sep 8, 2010
Watertown, MA – September 8, 2010 – Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agent...
Jun 1, 2010
Watertown, MA – June 1, 2010 – Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing. Excel Venture...
Apr 29, 2010
Watertown, MA – April 29, 2010 – Tetraphase Pharmaceuticals Inc., a biopharmaceutical company developing novel antibiotics based on proprietary synthetic chemistry technology, today announced that it will be participating in a session on drug discovery and development of novel treatments for drug-resist...
Oct 6, 2009
Watertown, MA –  October 06, 2009 – Tetraphase Pharmaceuticals Inc. announced today that it has closed the first tranche of its $25 million Series B financing to support the advancement of several novel and potent antibiotic drug candidates. This Series B Financing and first tranche ...
Sep 10, 2009
Watertown, MA –  September 10, 2009 –  Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial a...
Aug 6, 2008
Watertown, MA – August 6, 2008 –  Tetraphase Pharmaceuticals Inc. announced today that it has closed the second tranche of its $25 million Series A financing to support the advancement of several novel and potent antibiotic drug candidates. This second tranche of $15 million was fund...
FirstPrevious
...
15
NextLast
= add release to Briefcase